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Abstract
Background: Tissue factor (TF), expressed in endothelial cells (ECs) and enriched in human
atherosclerotic lesions, acts as a critical initiator of blood coagulation in acute coronary syndrome.
Basic fibroblast growth factor (bFGF) induces the proliferation and migration of ECs and plays a
role in angiogenesis and restoration of endothelial integrity. As TF is implicated in angiogenesis, we
studied the effect of bFGF on TF gene and protein expression. Methods: Human umbilical vein ECs
(HUVECs) were exposed to bFGF. TF mRNA was assessed by Northern blot and TF protein was
assessed by Western blot. TF promoter activity was assessed by transient transfection assay and
transcription factor was identified by electro mobility shift assay.
Results: bFGF increased TF mRNA and protein expression in HUVECs. Increased TF mRNA was
attenuated by inhibition of extracellular signal-regulated kinase kinase in human ECV304 cells.
Transient transfection assays of the human TF promoter-luciferase construct (-786/+121 bp)
demonstrated that bFGF induced transcription was dependent on the elements within the -197 to
-176 bp relative to the transcription start site of the human TF gene. This region contains NF-κB
like binding site. Electro mobility shift assay showed that bFGF increased nuclear translocation or
DNA binding of NF-κB transcription factor to TF promoter. Nucleotide substitution to disrupt NF-
κB like site reduced bFGF stimulated promoter activity. Fenofibric acid, an agonist ligand for the
peroxisome proliferator activated receptor-α, reduced basal and bFGF stimulated TF expression.
Conclusions: These results indicate that bFGF may increase TF production in ECs through
activation of transcription at NF-κB binding site, and control coagulation in vessel walls. Fibrate can
inhibit TF expression and therefore reduce the thrombogenecity of human atherosclerotic lesions.
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Tissue factor (TF) is an integral membrane protein, which
binds to coagulation factor VII/VIIa and initiates the coag-
ulation cascade [1]. TF expression can be inducible with
inflammatory cytokines, lipopolysaccharide (LPS) and
oxidized low-density lipoprotein in fibroblast, vascular
smooth muscle cells and monocytes in human atheroscle-
rotic lesions [2]. TF expressed on the surface of vascular
wall acts as the major procoagulant for thrombus forma-
tion [3].
Basic fibroblast growth factor (bFGF) elaborated by vascu-
lar cells can induce proliferation, morphological changes
and migration of smooth muscle cells and endothelial
cells (ECs) and modulate angiogenesis [4]. bFGF pro-
motes re-endothelialization with functional endothelium
after balloon injury or induced atherosclerosis and mod-
ulates TF expression in monocytes and smooth muscle
cells in vivo [5]. In ECs TF expression is regulated through
a promoter region, which encompasses potential binding
sites for activator protein-1 (AP-1), nuclear factor (NF)-κB
and SP-1 transcription factors [6]. LPS-induced TF expres-
sion in cells of the monocyte lineage requires functional
interaction between these transcription factors [2]. How-
ever, the influence, if any, of bFGF on synthesis of TF in
ECs has not been elucidated. The potential influence may
well contribute to physiologic or pathophysiologic conse-
quences of elaboration of bFGF.
The mechanisms inhibiting TF expression in ECs remain
largely unexplored. Fenofibric acid is a synthetic ligand
for the peroxisome proliferator activated receptor (PPAR)-
α [7]. PPARα, as well as the other members of the PPAR
family, are ligand-activated transcription factors belong-
ing to the nuclear hormone receptor superfamily. Certain
fatty acids and fibric acid derivative, which activates
PPARα, reduces TF expression in human monocyte cells
and macrophages in vitro [8]. However, to the best of our
knowledge, there has been no detailed documentation on
the effect of PPARα on TF expression in ECs under both
clinical and pathological settings. Therefore, in the
present study we characterized the influence of bFGF and
fibric acid on elaboration of TF in vitro by cultured ECs,
and sought to delineate potential mechanisms that may
underlie increased TF expression.
Methods
Materials
Human umbilical vein ECs (HUVECs) were obtained
from Clonetics (Walkersville, MD). Human ECV304 cell
line (ECV cells) was obtained from American Type Cul-
ture Collection (Manassas, VA). Penicillin-streptomycin
solution, medium 199, Dulbecco's modified Eagle's
media (DMEM) and trypsin were purchased from Sigma
(St. Louis, MO). Calf serum was obtained from Hyclone
(Logan, UT). PD98059 was from Research Biochemical
International and GF109203X and genistein were from
Sigma. All other chemicals were of the highest available
commercial grade.
Cell culture procedures
HUVECs and ECV cells were cultured and stimulated with
recombinant human bFGF (Genzyme, Minneapolis, MN)
as previously described [9]. HUVECs were incubated in
DMEM without serum and exposed to bFGF for 24 hr.
Cell lysates were prepared as previously described [5] and
stored at -80°C. ECV cells were cultured in medium 199
containing 10% calf serum. In some experiments fenofi-
bric acid (Kaken, Tokyo, Japan) was prepared as previ-
ously described [9], and ECV cells were preincubated with
fenofibric acid for 24 hr before exposure to bFGF. Cell via-
bility was determined by trypan blue exclusion and MTT
assay (Sigma).
Assays for TF antigen by Western blotting
TF antigen was assayed by Western blotting as previously
described [10]. In brief, equivalent amounts of cell lysates
were electrophoresed and transferred to polyvinylidene
difluoride membranes. Membranes were incubated with
0.2 µg/ml mouse anti-human TF IgG (American Diagnos-
tica, Greenwich, NY). Membranes were washed and incu-
bated with alkaline-phosphatase conjugated guinea pig
anti-mouse IgG (Sigma) diluted 1:5000. Membranes were
incubated with chemiluminescent enhancer system
(Immun-Star, Bio-Rad, Hercules, California) and exposed
to XAR film (Kodak, Rochester, NY), which was then
developed. Bands were quantified with the use of a densi-
tometer and ImageQuant software (Molecular Dynamics,
Sunnydale, CA).
Isolation of total RNA and Northern blotting
Total RNA was isolated by the acid guanidium thiocy-
anate-phenol-chloroform method. Northern blot analysis
was performed as described previously [9]. Gel-purified
polymerase chain reaction (PCR) fragments for TF (-786
to +121 bp) and β-actin, radiolabeled with α-32P-dCTP by
random priming, were used as probes. Autoradiography
was performed and band intensities were determined by
densitometric analysis.
Promoter-luciferase vector and expression plasmid
The human TF promoter 5' flanking region from -786 to
+121 (907 bp) was amplified by PCR from human
genomic DNA isolated from umbilical vein with the use
of forward PCR primer 5'-AGAGGCAAACTGCCAGATGT-
3' (-786 to -766) and the reverse primer 5'-
TGTCTACCAGTTGGCGGCCG-3' (+101 to +121), respec-
tively [11]. The PCR product was gel-purified and sub-
cloned into the multiple cloning sites of the pT7Blue T-
Vector (Novagen, Madison, WI). The T-vector wasPage 2 of 9
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multiple cloning sites of the promoterless Renilla luci-
ferase reporter gene vector pRL-null (Promega, Madison,
WI). Basal expression of luciferase activity of the TF pro-
moter vector was detected by the TF Full (-786/+121) luci-
ferase vector, which includes two AP-1, three SP-1 (Egr-1),
and two NF-κB binding sites. The 5' deletion mutants
were generated by PCR with the use of 5' primers comple-
mentary to the TF gene sequence. Deletion mutants of TF
promoter vectors were constructed as follows: pTF 1F
(-513/+121) luciferase lacks distal AP-1 like binding site,
but retains two NF-κB like binding sites, proximal AP-1
like binding site and distal SP-1/Egr-1 like binding site.
pTF 2F (-318/+121) luciferase lacks distal NF-κB like
binding site, but retains proximal AP-1 like binding site,
proximal NF-κB like binding site and distal SP-1/Egr-1
like binding site. pTF 3F (-197/+121) luciferase lacks both
AP-1 like binding sites and distal NF-κB like binding site,
but retains proximal NF-κB like binding site and distal SP-
1/Egr-1 like binding site. pTF 4F (-176/+121) luciferase
lacks proximal NF-κB like binding site, but retains distal
SP-1/Egr-1 like binding site. pTF 5F (-129/+121) luci-
ferase lacks distal SP-1/Egr-1 like binding site. Point muta-
tion of TF promoter vectors was also constructed [9]. Basal
expression of luciferase activity of TF promoter vector was
detected by the TF Full luciferase vector, which has normal
proximal NF-κB like site (5'-CGGAGTTTCC-3'). One
mutation vector has two point mutations in NF-κB like
site as underlined (5'-CGGAGTTTGG-3') and another
mutation vector has two point mutations in NF-κB like
site (5'-CGGAGTTTGG-3') and one point mutation in SP-
1/Egr-1 like site (5'-AGGCAGGGCAGGGGTG-3') as
underlined.
DNA transfection and the luciferase assay
DNA transfection and the luciferase assay were performed
as previously described [9]. ECV cells of approximately
80% confluency were cotransfected with each TF pro-
moter Renilla luciferase fusion DNA reporter construct (20
µg of pRL vector) and a Firefly luciferase pGL vector to
control for transfection efficiency (20 µg) introduced by
electroporation (240 V, 960 µFD). These cells were cul-
tured in DMEM with 10% calf serum for 24 hours, stimu-
lated with bFGF (10 ng/ml) in DMEM containing 10%
calf serum for 24 hours and harvested. Cell lysate luci-
ferase activity was measured with Dual-Luciferase
Reporter Assay System (Promega). Normalized luciferase
activity was calculated as the ratio of luciferase activity to
control vector activity. Results for each reporter construct
were expressed as fold induction compared with results in
transfected, unstimulated cells.
Electrophoretic mobility shift assay
For electrophoretic mobility shift assay (EMSA) ECV cells
were preincubated for 24 hours with fenofibrate 100
µmol/L and then stimulated for 2 hours with bFGF 100
ng/ml before nuclear extracts were prepared. The NF-κB
oligonucleotide
(ACGCGTCGGAGTTTCCTTGAACGGAGTTTCCGATC)
spanning the 2 tandem NF-κB like sites (as underlined
above) in the human TF promoter was end-labeled with
[α-32P]dCTP (3000 Ci/mmol) by Klenow fragment of
DNA polymerase I (Amersham Life Science, Buckingham-
shire, England) and purified with NucTrap column (Strat-
agene, La Jolla, CA). Nuclear extracts (0.3 µg) were
incubated with the labeled NF-κB like oligonucleotide
under standard conditions. In the indicated experiments
nuclear extracts were incubated with rabbit polyclonal
anti-NFκB p50, rabbit polyclonal anti-NFκB p65 or
mouse monoclonal anti-c-Rel IgG (Santa Cruz Biotech-
nology, Santa Cruz, CA) or nonspecific IgG before the
addition of radiolabeled NF-κB probes. DNA-protein
complexes were electrophoretically separated. Specificity
was determined by addition of an excess of unlabeled NF-
κB oligonucleotide to the nuclear extracts before forma-
tion of DNA-protein complexes.
Statistics
Data are means ± SD. Differences were assessed by analy-
sis of variance with Bonferroni's least significant post hoc
tests for comparisons within multiple groups. Significance
was defined as P < 0.05.
Results
Effects of bFGF on TF expression in ECs
bFGF (100 ng/ml) increased TF mRNA accumulation in
HUVECs as assessed by Northern blotting (Figure 1A). An
increased response to bFGF was evident by 1 hr with fur-
ther increases at 2 hr and 4 hr but it decreased after 8 hr.
bFGF increased TF protein accumulation in the cell lysate
in a concentration-dependent fashion (Figure 1B). Peak
effects were seen with 10 ng/ml bFGF. An increase in TF
mRNA expression induced by bFGF was seen with ECV
cells as well (Figure 1C). bFGF increased TF protein accu-
mulation in the cell lysate in a concentration-dependent
fashion (Figure 1D). Peak effects were seen with 10 ng/ml.
The response was diminished somewhat with concentra-
tions of 100 ng/ml. Total protein content in the cell
lysates was not altered by bFGF (results not shown).
Effects of PD 98059 and GF109203X on TF mRNA
To investigate the intracellular mechanisms involved in
the induction of TF mRNA ECV cells were treated for 1 hr
with each of the various inhibitors of intracellular signal-
ing pathway before addition of bFGF (Figure 2). Inhibi-
tion of extracellular signal-regulated kinase (ERK) kinase
with PD98059 blocked basal and bFGF stimulated TF
mRNA levels. In contrast, GF109203X, an inhibitor of
protein kinase C (PKC) pathway, blocked only bFGF stim-
ulated TF mRNA levels and had no significant effect onPage 3 of 9
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kinase, had no significant effect, either (result not shown).
β-actin mRNA levels did not change in any experimental
conditions.
Determination of the DNA regions critical for basal and 
bFGF inducible TF transcriptional activity
To identify the basal and bFGF responsive elements in the
5' flanking region of the TF gene, transient transfections
with several TF promoter-luciferase reporter constructs
were performed in ECV cells (Figure 3). With progressive
5' deletion of the TF promoter basal activity was reduced
first (TF Full vs pTF1) (Figure 3A). Lower basal promoter
activity observed in pTF1 suggests that the region between
-786 bp and -513 bp may contain enhancer element(s).
Furthermore, upon deletion of the region at -513 to -197
bp basal activity was increased (pTF3 vs pTF1, pTF3 vs
pTF2), suggesting that distal NF-κB and proximal AP-1
sites are not so important for basal promoter activity. But
deletion of the region at -197 to -129 bp reduced basal
(A) Upregulation of TF mRNA in HUVECs stimulated with bFGF (100 ng/ml) for 4 hrFigure 1
(A) Upregulation of TF mRNA in HUVECs stimulated with bFGF (100 ng/ml) for 4 hr. The expressions of TF mRNA and of β-
actin were determined by Northern blot analysis as described in Methods (n = 3). A representative autoradiograph is shown. 
(B) Effects of bFGF on concentrations of TF in HUVECs. Confluent cells were serum starved for 24 hr and then incubated with 
fresh serum free media containing bFGF (0 – 100 ng/ml) for 4 hr. Concentrations of TF in cell lysates were assayed by Western 
blotting as described in Methods (n= 6). The upper panel shows a representative blot from six separate experiments. Values 
are means ± SD of fold increase over control without bFGF. *P < 0.05 as compared to control. (C) Upregulation of TF mRNA 
in ECV cells stimulated with bFGF (0–100 ng/ml) for 4 hr. Expressions of TF mRNA and of β-actin were determined by North-
ern blot analysis as described in Methods (n = 3). A representative autoradiograph is shown. (D) Effects of bFGF on concentra-
tions of TF in ECV cells. Confluent cells were serum starved for 24 hr and then incubated with fresh serum free media 
containing bFGF (0 – 100 ng/ml) for 4 hr. Concentrations of TF in cell lysates were assayed by Western blotting as described in 
Methods (n = 6). The upper panel shows a representative blot from six separate experiments. Values are means ± SD of fold 
increase over control without bFGF. *P < 0.05 as compared to control.Page 4 of 9
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full vs pTF5), suggesting that proximal NF-κB and distal
SP-1/Egr-1 sites are important for basal promoter activity.
To identify the 5' flanking region of the TF gene responsi-
ble for the effects of bFGF, transient transfections with sev-
eral TF promoter-luciferase reporter constructs were
performed in ECV cells. bFGF increased promoter driven
luciferase activity. Relative to the largest promoter frag-
ment tested, bFGF effect was reduced with deletion of the
region at -786 to -513 bp and -513 to 318 bp. Deletion of
the region at -197 to -176 bp completely abolished the
bFGF effect. These data indicate that the major sequence
determinant of responsiveness to bFGF resides between -
197 to -176 bp. This region contains the binding site for
NF-κB. Deletion of the region at -176 to -129 bp, which
contains the binding site for SP-1/Egr-1, resulted in no
further reduction. To further characterize the responsible
region a mutant construct containing 2-nucleotide substi-
tutions in proximal NF-κB like site was generated. Com-
pared with the bFGF induced increased promoter activity
in the wild-type substitutions in the NF-κB like site
reduced both basal and bFGF inducible promoter activi-
ties (Figure 3B). Substitutions in both NF-κB like site and
SP-1/Egr-1 like site further reduced basal promoter activ-
ity. These data indicate that proximal NF-κB element at -
197 to -176 bp and distal SP-1/Egr-1 element at -176 to -
129 bp regulate basal TF promoter activity, and that prox-
imal NF-κB element at -197 to -176 bp regulates bFGF
inducible TF promoter activity.
Effects of PD98059 and GF109203X on TF mRNAFigure 2
Effects of PD98059 and GF109203X on TF mRNA. (A) A representative autoradiograph from three separate experiments. (B) 
Effects of PD98059 (30 µM) and GF109203X (2 µM) on TF mRNA levels. ECV cells were incubated with or without indicated 
inhibitors for 1 hr and then bFGF was added. Cells were incubated for 4 hr. Total RNA was isolated and analyzed by Northern 
blot. PAI-1 mRNA levels were analyzed by densitometry and normalized to β-actin signals. Values are means ± SD (n = 6) of 
fold increase over control without bFGF. *p < 0.05 and **p < 0.01.Page 5 of 9
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To determine whether NF-κB binding protein was respon-
sible for bFGF effect EMSA was performed using
oligonucleotides corresponding to the TF NF-κB like site.
bFGF induced nuclear translocation and DNA binding of
the transcription factor NF-κB to the TF promoter (Figure
4). The addition of an excess of cold probe inhibited
DNA-protein complex formation. The addition of the p65
antibody induced a dramatic shift of the band. The addi-
tion of the p50 antibody effectively inhibited interaction
between NF-κB protein and oligonucleotide containing
NF-κB binding site without a dramatic shift of the band.
The addition of the c-Rel antibody did not affect the
migration of the band. These results show that NF-κB
complexes contained p65 predominantly and p50 and c-
Rel in only a minor portion of the band.
Effects of fenofibric acid
Fenofibric acid diminished both basal and bFGF induci-
ble TF mRNA expression in ECV cells as assessed by
Northern blotting (Figure 5A,5B). When fenofibric acid
(100 µM) was present in media of ECV cells transfected
with the TF promoter-luciferase reporter construct, both
basal TF promoter activity and bFGF (100 ng/ml) stimu-
(A) Effects of progressive 5' deletions of the TF gene on basal and bFGF inducible TF transcriptional activityFigur  3
(A) Effects of progressive 5' deletions of the TF gene on basal and bFGF inducible TF transcriptional activity. For determination 
of promoter activity raw data were tabulated as the ratio of firefly luciferase activity to that of Renilla luciferase activity (means 
± SD, n = 18), and values were reported as relative to the value for the control plasmid (assigned a value of 100). *p < 0.05 and 
**p < 0.01. Constructs of transfected plasmids are indicated at the left panel. TATA: TATA box. (B) Effects of point mutations 
in NF-κB like site and SP-1/Egr-1 like site on TF promoter activity (n = 3). Promoter activity was determined and values were 
reported as relative to the value for the TF full without bFGF stimulation. Basal expression of luciferase activity of TF promoter 
vector was detected by the TF Full luciferase vector, which has normal NF-κB like site (5'-CGGAGTTTCC-3'). One mutation 
vector has two point mutations in NF-κB like site as underlined (5'-CGGAGTTTGG-3'). Another mutation vector has two 
point mutations in NF-κB like site as underlined (5'-CGGAGTTTGG-3') and one point mutation in SP-1/Egr-1 like site (5'-
AGGCAGGGCAGGGGTG-3'). *p < 0.05 and **p < 0.01.Page 6 of 9
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Thus, fenofibric acid inhibits TF expression at least partly
at the level of transcription. Fenofibric acid did not inhibit
bFGF induced nuclear translocation or DNA binding of
NF-κB like transcription factor to the TF promoter (Figure
4). Fenofibric acid markedly diminished but did not
totally abolish TF protein accumulation in the lysate of
ECV cells exposed to bFGF (100 ng/ml) (Figure 5D). At a
concentration of 100 µM it suppressed both basal and
bFGF inducible TF protein accumulation. Cell viability
was unaffected by fenofibric acid at the concentrations
used (results not shown).
Discussion
In this study bFGF was shown to influence production of
TF in ECs. Increased TF protein correlated with increased
mRNA and activity of the promoter. Fenofibric acid, an
agonist ligand for PPARα, reduced basal and bFGF stimu-
lated TF expression.
The binding of bFGF to its specific receptor triggers a cas-
cade of events leading to signal transductions including
ERK, mitogen-activated protein kinase, Ras and PKC path-
ways [12,13]. The results in this study suggest that the
induction mechanism of TF expression by bFGF may
involve ERK kinase. These results are consistent with the
recent study, which demonstrated that bFGF induced I-κB
degradation and NF-κB activation through ERK1/2 path-
way in smooth muscle cells [13]. In addition, platelet-
derived growth factor induces TF expression in smooth
muscle cells by an ERK pathway-dependent mechanism
and, in part, by Ras and PKC pathway-dependent mecha-
nisms [14] and ERK activity is required for NF-κB activa-
tion by IL-1β [15]. Our study demonstrated that bFGF
EMSA of ECV cells stimulated with bFGF for 2 hrFigure 4
EMSA of ECV cells stimulated with bFGF for 2 hr. Some cells were pretreated with fenofibric acid for 24 hr before bFGF stim-
ulation. EMSA was performed using probes from NF-κB like site of TF promoter and anti-human p50, p65 and C-Rel IgGs or 
control rabbit IgG. The panel shows a representative autoradiograph from three separate experiments.Page 7 of 9
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ECs.
Deletion analysis of TF promoter revealed that a region
between -197 bp and -176 bp contains the elements
mediating the bFGF response. A search for the putative
transcription factor binding sites within this region
showed it to contain an NF-κB like site (CGGAGTTTCC)
at -188 to -178 bp. Furthermore, basal promoter activity
was regulated by this NF-κB like site and by SP-1/Egr-1
like site (GAGGCGGGGCAGGGGT) present at -169 to -
154 bp. NF-κB, AP-1 and SP-1 elements in human TF pro-
moter are involved in the activation of TF gene in ECs
[6,16]. Our results suggest that NF-κB element is impor-
Downregulation of TF by fenofibric acidFigure 5
Downregulation of TF by fenofibric acid. (A) Confluent ECV304 cells were serum starved for 24 hr and incubated with fresh 
serum free media containing fenofibric acid (100 µM) for 20 hr. The magnitudes of expression of TF mRNA and of β-actin 
were determined by Northern blot analysis as described in Methods (n = 3). A representative autoradiograph is shown on the 
left. Values are means ± SD (n = 6) of percent change over control without bFGF. **p < 0.01 compared to control. (B) Conflu-
ent ECV304 cells were serum starved for 24 hr and incubated with fresh serum free media containing fenofibric acid (100 µM) 
for 20 hr, and exposed to bFGF (10–100 ng/ml) for 4 hr. The magnitudes of expression of TF mRNA and of β-actin were 
determined by Northern blot analysis as described in Methods (n = 3). A representative autoradiograph is shown on the left. 
Values are means ± SD (n = 6) of percent change over control without bFGF. **p < 0.01 compared to control. (C) Effects of 
fenofibric acid (100 µM) on basal and bFGF inducible TF transcriptional activity. For determination of promoter activity raw 
data were tabulated as the ratio of firefly luciferase activity to that of Renilla luciferase activity (means ± SD, n = 4), and values 
were reported as relative to the value for the control plasmid (assigned a value of 100). FA: fenofibric acid. *p < 0.05 (D) 
Effects of fenofibric acid on the concentration of TF in ECV cell lysates. Confluent cells were serum starved for 24 hr, incu-
bated with fresh serum free media with or without fenofibric acid (100 µM) for 20 hr, and exposed to bFGF (100 ng/ml) for 24 
hr. Concentrations of TF in cell lysates were assayed by Western blotting. Values are means ± SD (n = 6) of fold increase over 
control without bFGF. FA: fenofibric acid. *p < 0.05Page 8 of 9
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tant in TF gene activation after bFGF stimulation in ECs.
In addition, SP-1/Egr-1 element is likely required for basal
transcription from the TF promoter. The role of transcrip-
tion repressor of the TF gene in ECs [17] needs further
investigation.
PPARα negatively regulates vascular inflammatory gene
response by negative cross-talk with NF-κB and AP-1 [18].
PPARα is expressed in ECV cells [19]. PPARα ligand,
fenofibric acid, diminished both basal and bFGF
inducible expression of TF, potentially reducing the
thrombogenicity of atherosclerotic lesions. Deletion of
the promoter region containing the NF-κB site inhibited
the effect of bFGF and EMSA suggested that fenofibric acid
did not inhibit nuclear translocation or DNA binding of
the NF-κB like transcriptional factor to the TF promoter.
Thus, inhibition of TF synthesis by fenofibric acid may
occur transcriptionally as a result of PPARα repression of
NF-κB signaling. Further studies are in progress to eluci-
date the mechanism of fenofibric acid effect using cells
from arterial sources. These data indicate that activation of
PPARα results in the downregulation of the TF gene and
provide new insight into how PPARα-activating fibric acid
derivatives might influence atherothrombosis in patients
with vascular disease. The present study tested a novel role
for PPARα in the control of atherosclerotic plaque throm-
bogenicity through its effects on TF expression in ECs and
suggested that fibric acid may reduce thrombotic compli-
cations of atherosclerosis.
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